

Global Hepatitis Drug Market: Market Segments: By Disease Type (Hepatitis A Hepatitis B, and Hepatitis C); By Route of Administration(OralandInjection); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

<https://marketpublishers.com/r/G5F66F1E7729EN.html>

Date: May 2024

Pages: 161

Price: US\$ 5,000.00 (Single User License)

ID: G5F66F1E7729EN

Abstracts

Product Overview

Hepatitis refers to a disease of the liver that is inflammatory. Hepatitis is a medical condition in which the liver is mainly damaged and the digestive system and brain are further compromised in the long run. There are three primary forms of hepatitis: HAV, HBV, and HCV. HCV is a big public health issue where, due to inflammation, the liver gets inflamed. Certain medications, toxins, heavy alcohol use, bacterial and viral infections may cause a hepatitis infection. Identified as hepatitis, viral liver infections include hepatitis A, B, C, D, and E. Hepatitis A is a short-term, acute infection, while hepatitis B, C, and D are most likely to become chronic and permanent. In pregnant women, hepatitis E is typically acute but may be especially severe, increasing maternal and fetal mortality and morbidity.

Market Highlights

Global Hepatitis Drug Market is expected to project a notable CAGR of XX.X% in 2030. Global Hepatitis Drug Market to surpass USD XXXX million by 2030 from USD XXXX million in 2018 at a CAGR of XX% throughout the forecast period, i.e. 2019-30. The worldwide rise in hepatitis prevalence is expected to fuel the growth of the demand for hepatitis drugs. In addition, numerous companies are concentrating on research and development to extend their hepatitis drug treatment portfolio, which is expected to fuel the growth of the hepatitis drug market.

Global Hepatitis Drug Market: Segments

Global Hepatitis Drug Market: Market Segments: By Disease Type (Hepatitis A Hepatitis B, and Hepatitis C); By...

Hepatitis C Segment to grow with the highest CAGR during 2019-30

Global Hepatitis Drug Market is segmented by type into hepatitis A, B, C, and others. The greater market share in 2018 was accounted for by the hepatitis C segment and is expected to see the highest growth during the forecast period. A growing number of events involving various forms of hepatitis, including hepatitis B and hepatitis C, play an important role in driving the growth of the demand for hepatitis drugs. Hepatitis is recognized as a leading cause of mortality, while hepatitis C is responsible for around 500,000 deaths per year. The rise in the prevalence of hepatitis has also increased the overall demand for medications to cure and control the disease. Olysio and Sovaldi's second-generation DAAs are the key drivers of the hepatitis drug market. The DAAs of the second generation are more successful and have fewer adverse effects. IFN therapies for the treatment of hepatitis C are currently being established by market players, and this significant emphasis in this segment is expected to fuel the growth of the hepatitis drug market in the future.

Global Hepatitis Drug Market: Market Dynamics

Drivers

Prevalence of Hepatitis Infection

Infection with the hepatitis virus is one of the key global public health risks and is essentially a primary cause for the emergence of hepatic cirrhosis and hepatocellular carcinoma. The increasing number of infected populations increased consumption of alcohol and narcotics, and improved access to medicinal products for hepatitis are also increasing. The launch of generic hepatitis drugs has also changed the nature of the industry around the world. With the rise in people being able to buy generic versions, it is expected that drug use rates will grow dramatically over the next few years.

Increasing participation of market players and government associations

In addition, growing involvement by major players and government associations plays a pivotal role in driving the growth of the hepatitis drug market in the form of promotion and funding. These programs, in turn, promote the advancement of drug treatments, facilitate diagnosis, and provide patients with tailor-made solutions. In addition, factors such as the rise in injection drug users, the rise in awareness, the prevalence of unmet needs, and the anticipated launch of new drugs are expected to drive the growth of the market over the forecast period.

Restrain

High cost of Hepatitis Drug products

Factors such as longer development and approval periods for hepatitis drugs are expected to impede the growth of the demand for hepatitis drugs. As their production

process is labor-intensive and involves costly drug intermediates and active pharmaceutical ingredients, the manufacture of hepatitis drugs is extremely expensive. The high capital requirement for the development and commercialization of medicinal products indicated for the treatment of hepatitis is therefore a key constraint that impedes the growth of the market for hepatitis drugs.

Global Hepatitis Drug Market: Key Players

F. Hoffmann-La Roche

Company Overview

Business Strategy

Key Product Offerings

Financial Performance

Key Performance Indicators

Risk Analysis

Recent Development

Regional Presence

SWOT Analysis

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Vertex Pharmaceuticals

Abbvie

Achillion Pharmaceuticals

Bristol-Myers Squibb

Global Hepatitis Drug Market: Regions

Global Hepatitis Drug Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA.

Global Hepatitis Drug Market in North America held the largest market share of XX.X% in the year 2018. The comparatively greater affordability of the patient population and knowledge of advanced therapeutics in the area was primarily due to the high demand in the U.S. Some of the main factors leading to this high proportion are the availability of well-developed healthcare facilities, insurance, and access to the most advanced medicines. During the forecast period, the Asia Pacific market is expected to see the fastest growth rate of 5.8 percent. The high burden of disease increased access to drugs, improved healthcare & sanitation, and increased awareness of hepatitis vaccination are expected to positively reinforce the growth prospects in the region.

Competitive Landscape:

Global Hepatitis Drug market, which is highly competitive, consists of several major players such as Dynavax Technologies Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novartis AG, AbbVie Inc., Gilead Sciences Inc., hold a substantial market share in the Global Hepatitis Drug market. Other players analyzed in this report are Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline plc, and Bristol-Myers Squibb Company among others

Global Hepatitis Drug Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada

Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe

APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC

MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Hepatitis Drug Market report also contains analysis on:

Global Hepatitis Drug Market Segments:

By Type:

Hepatitis A

Hepatitis B

Baraclude

Viread

Tyzeka

Hepsera

Hepatitis C

Sovaldi

OLYSIO

Harvoni

Pegasys

PegIntron

Victrelis

Others

Others

By Route of Administration:

Oral

Injection

Hepatitis Drug Market Dynamics

Hepatitis Drug Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies Involved in the Market

Value Chain of the Market

Market Drivers and Restraints

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL HEPATITIS DRUG MARKET

- 2.1. Product Overview
- 2.2. Market Definition
- 2.3. Segmentation
- 2.4. Assumptions and Acronyms

3. RESEARCH METHODOLOGY

- 3.1. Research Objectives
- 3.2. Primary Research
- 3.3. Secondary Research
- 3.4. Forecast Model
- 3.5. Market Size Estimation

4. AVERAGE PRICING ANALYSIS

5. MACRO-ECONOMIC INDICATORS

6. MARKET DYNAMICS

- 6.1. Growth Drivers
- 6.2. Restraints
- 6.3. Opportunity
- 6.4. Trends

7. CORRELATION & REGRESSION ANALYSIS

- 7.1. Correlation Matrix
- 7.2. Regression Matrix

8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE

9. RISK ANALYSIS

9.1. Demand Risk Analysis

9.2. Supply Risk Analysis

10. GLOBAL HOSPITAL BEDS MARKET ANALYSIS

10.1. Porters Five Forces

10.1.1. Threat of New Entrants

10.1.2. Bargaining Power of Suppliers

10.1.3. Threat of Substitutes

10.1.4. Rivalry

10.2. PEST Analysis

10.2.1. Political

10.2.2. Economic

10.2.3. Social

10.2.4. Technological

11. GLOBAL HEPATITIS DRUG MARKET

11.1. Market Size & forecast, 2019A-2030F

11.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. GLOBAL HEPATITIS DRUG MARKET: MARKET SEGMENTATION

12.1. By Regions

12.1.1. North America:(U.S. and Canada)

12.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)

12.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)

12.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)

12.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

12.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.2. By Type: Market Share (2020-2030F)

12.2.1. Hepatitis A, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)
2020-2030F

12.2.2. Hepatitis B, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)
2020-2030F

12.2.3. Hepatitis C, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)
2020-2030F

12.2.4. Others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.3. By Route of Administration: Market Share (2020-2030F)

12.3.1. Oral, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.3.2. Injection, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

13. COMPANY PROFILE

13.1. Merck & Co. Inc

13.1.1. Company Overview

13.1.2. Company Total Revenue (Financials)

13.1.3. Market Potential

13.1.4. Global Presence

13.1.5. Key Performance Indicators

13.1.6. SWOT Analysis

13.1.7. Product Launch

13.2. AbbVie Inc.

13.3. Bristol Myers Squibb Company

13.4. Hoffmann-La Roche Ltd.

13.5. LAURUS Labs

13.6. Zydus Cadila

13.7. Hetero Healthcare Limited

13.8. GlaxoSmithKline PLC

13.9. Cipla Inc.

13.10. Other Prominent Players

Consultant Recommendation

****The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.**

I would like to order

Product name: Global Hepatitis Drug Market: Market Segments: By Disease Type (Hepatitis A Hepatitis B, and Hepatitis C); By Route of Administration(OralandInjection); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

Product link: <https://marketpublishers.com/r/G5F66F1E7729EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5F66F1E7729EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970